Dishman Carbogen Amcis Reports Significant Profit Growth Amid Rising Interest Expenses

Dishman Carbogen Amcis, a small-cap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment that reflects notable shifts in its financial metrics. The company's performance for the quarter ending March 2025 has been characterized by significant growth, particularly in profit before tax less other income, which reached Rs 31.48 crore, marking a growth rate of 159.10%. Additionally, the company reported its highest PBDIT at Rs 152.69 crore and an operating profit to net sales ratio of 21.32%, indicating a robust operational efficiency.
Despite these positive indicators, the company faces challenges, particularly with interest expenses, which have risen to Rs 90.90 crore, reflecting a growth of 32.58% over the latest six months. The valuation metrics also suggest a very attractive position, with a PE ratio of 188.30 and an enterprise value to capital employed ratio of 0.79, indicating a favorable comparison to industry peers.

The technical landscape for Dishman Carbogen has shifted to a mildly bullish stance, supported by positive signals from MACD and Bollinger Bands. The stock has demonstrated strong returns, outperforming the BSE 500 over various time frames, including a 42.46% return over the past year.

For more insights on Dishman Carbogen Amcis and its financial trends, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.